Immuron Ltd
IMC
Company Profile
Business description
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Contact
Chapman Street
Unit 10, 25-37
Blackburn North
MelbourneVIC3130
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
7
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,624.90 | 6.60 | -0.08% |
| CAC 40 | 7,788.10 | 38.69 | -0.49% |
| DAX 40 | 24,038.19 | 188.30 | -0.78% |
| Dow JONES (US) | 42,235.43 | 108.22 | -0.26% |
| FTSE 100 | 8,726.01 | 52.04 | -0.59% |
| HKSE | 23,258.31 | 123.68 | -0.53% |
| NASDAQ | 19,219.07 | 19.91 | 0.10% |
| Nikkei 225 | 37,722.40 | 1.71 | -0.00% |
| NZX 50 Index | 12,362.26 | 220.07 | -1.75% |
| S&P 500 | 5,916.98 | 4.56 | -0.08% |
| S&P/ASX 200 | 8,396.90 | 10.70 | -0.13% |
| SSE Composite Index | 3,339.93 | 0.76 | -0.02% |